• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

    3/22/21 8:26:55 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVPH alert in real time by email

    -Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market-

    -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved-

    CUPERTINO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced its financial results for 2020 and provided a corporate update.

    “We are thrilled to enter this new year as a public company following the recent close of our merger in December. Following our listing on the NASDAQ Capital Market, we believe our interactions with the investor community and strategic alliances have gained significant momentum. This inflection point represents the progress we have made with our innovative pipeline,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “We continue to drive forward with our lead asset, brilaroxazine (RP5063), as our primary focus is to complete the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia. With the previous successful completion of our Phase 2 trial in patients with acute schizophrenia, we are excited at the prospect of bringing brilaroxazine into a Phase 3 clinical trial in mid-2021, assuming the Company achieves its fundraising goals. We look forward to providing additional updates as we continue to drive further innovation in our pipeline and intend to advance our late-stage clinical programs.”        

    2020 Full Year Highlights and Recent Developments

    Clinical Developments

    Ready for Phase 3 study of brilaroxazine for patients with schizophrenia
    Reviva previously completed a Phase 2 study of brilaroxazine in patients with acute schizophrenia and schizoaffective disorders. Brilaroxazine met its primary endpoint of reduction in PANSS total score and was well-tolerated. Reviva previously had a successful End-of-Phase 2 (EOP2) meeting with FDA and the agency agreed to consider granting brilaroxazine a “Superior Safety Label Claim” for the treatment of schizophrenia if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 study in schizophrenia. Reviva is planning for a multi-center Phase 3 study of RP5063 that is expected to commence in mid-2021, assuming completion of the Company’s fundraising goals.

    Prepared for Phase 2 studies of brilaroxazine for patients with pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF)
    Reviva has been granted Orphan Drug Designation for brilaroxazine for the treatment of PAH and IPF. The FDA has also previously reviewed and provided guidance on the Phase 2/3 clinical development of RP5063 and a potential Disease Modifying Agent label.        

    Extensive Intellectual Property
    Reviva owns an extensive patent portfolio that includes issued patents and pending patent applications covering compositions of matter and methods of use of our product candidates RP5063 and RP1208, as well as related compounds. Our robust portfolio consists of 60 granted patents and 22 pending patent applications in the United States and in foreign countries as of December 31, 2020.

    Enhanced Financial Profile

    Tenzing Acquisition Corp Merger Agreement
    In December 2020, Reviva closed a merger with Tenzing Acquisition Corp., a special purpose acquisition company. Common stock of the merged company commenced trading on the NASDAQ Capital Market under the new ticker symbol “RVPH” as of December 15, 2020.

    Expanded Leadership Team
    In October 2020, Reviva appointed Narayan Prabhu as Chief Financial Officer. Mr. Prabhu brings over 20 years of finance leadership and experience in biotechnology and information technology at both Fortune 500 companies and early-stage ventures. Prior to Reviva, he served as the Chief Financial Officer at Sony Biotechnology, a biotechnology company focused on reagents, flow cytometry, and spectral imaging for advanced biomedical and immunotherapy research. Mr. Prabhu received his B.S. in Accounting & Finance from Indiana University at Bloomington - Kelley School of Business and MBA from the University of California at Berkeley - Haas School of Business.

    Board of Advisors

    • Daphne Karydas – Strategic Finance and Business Development
    • John Kane, MD – Neuropsychiatry - Schizophrenia, Bipolar and MDD
    • Leslie Citrome – Neuropsychiatry - Schizophrenia, Bipolar and MDD
    • Martin Kolb, MD, PhD – Pulmonary Medicine – Idiopathic pulmonary fibrosis (IPF)
    • Roham Zamanian, MD – Pulmonary Medicine – Pulmonary arterial hypertension (PAH)

    Anticipated Events and Targeted Milestones for 2021

    • Meet with the FDA to discuss final study design of the Phase 3
    • Initiate Phase 3 Double-blind, Placebo-controlled, Multicenter Trial in 360 patients, assuming the Company achieves its fundraising goals
    • Pursue partnership and financing opportunities for the development of our pipeline
    • Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations

    2020 Financial Results

    The Company reported a net loss of approximately $3.8 million, or $1.24 per share, for the year ended December 31, 2020, compared to a net loss of approximately $847,000, or $0.31 per share, for the year ended December 31, 2019.

    Net cash provided by financing activities in the year ended December 31, 2020 of $12.5 million primarily related to proceeds of $9.4 million from the close of the merger and $3.1 million from the issuance of convertible promissory notes.

    As of December 31, 2020, the Company’s cash and cash equivalents totaled approximately $8.8 million compared to approximately $193 as of December 31, 2019.

    Reviva believes that based on the current operating plan and financial resources, the Company’s cash and cash equivalents at December 31, 2020 will be sufficient to cover general operating expenses through 2021.

    About Reviva
    Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.

    Forward-Looking Statements
    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Corporate Contact:
    Reviva Pharmaceuticals Holdings, Inc.
    Laxminarayan Bhat, PhD
    www.revivapharma.com

    Investor Relations Contact:
    LifeSci Advisors, LLC
    Bruce Mackle
    [email protected]


    Get the next $RVPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVPH

    DatePrice TargetRatingAnalyst
    9/20/2023$12.00Buy
    ROTH MKM
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    7/26/2021$10.00Buy
    Maxim Group
    More analyst ratings

    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Narayan Prabhu

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:51 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Bhat Laxminarayan

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      2/18/25 4:30:30 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Patel Purav

      4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

      12/12/24 4:35:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Financials

    Live finance-specific insights

    See more
    • Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

      - Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast

      10/30/23 7:30:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

      9/29/23 9:00:00 AM ET
      $AREC
      $RVPH
      $STSS
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reviva to Participate in the Citizens Life Sciences Conference

      CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY. Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here About Reviva Reviva is

      4/29/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

      CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster

      4/24/25 8:00:00 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

      – Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024

      3/31/25 4:05:15 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    SEC Filings

    See more
    • SEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.

      S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      4/3/25 7:55:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Reviva Pharmaceuticals Holdings Inc.

      NT 10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 5:16:54 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)

      3/31/25 4:12:22 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

      ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      9/20/23 7:22:47 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

      The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

      6/8/23 7:41:12 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Reviva Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      1/24/22 6:07:15 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 5:16:56 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 4:15:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      8/23/24 4:07:26 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care